Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 5.868
Filter
1.
Addict Sci Clin Pract ; 19(1): 49, 2024 Jun 13.
Article in English | MEDLINE | ID: mdl-38872214

ABSTRACT

BACKGROUND: The 15-method is a targeted screening and treatment approach for alcohol problems in primary care. The 15-method used in primary care has proven as effective as specialized treatment for mild to moderate alcohol dependence in Sweden. A feasibility study of the 15-method in Danish primary care found the method acceptable and feasible. AIMS: To evaluate the effectiveness of the 15-method in a Danish primary care setting in (1) lowering the proportion of patients exceeding the Danish low-risk alcohol consumption limit of ten standard units per week and a maximum of four standard units on a single day for men and women, and (2) increasing the likelihood of alcohol use being addressed during a consultation in general practice. Further, the rate of prescribed pharmacological treatment for alcohol problems (Disulfiram, Naltrexone, Acamprosate, and Nalmefene) will be measured along with the use of the biomarkers Alanine Transaminase and Gamma-Glutamyl Transferase. METHODS: Stepped wedge cluster randomized controlled trial in sixteen general practices in the Region of Southern Denmark. Following a three-month baseline, the practices are randomly assigned to launch dates in one of four clusters. General practitioners and nurses receive three hours of training in the 15-method before launch. Patient questionnaires will collect data on alcohol consumption levels among patients affiliated with the practices. The healthcare professionals will register consultations in which alcohol is addressed in their patient filing system. Pharmacological treatment rates and the use of biomarkers will be collected through Danish national registries. The study follows the Medical Research Council's guidelines for developing and evaluating complex interventions. DISCUSSION: From the patient's perspective, the 15-method may help identify alcohol-related problems at an earlier stage with flexible treatment offers in a familiar setting. For healthcare professionals, it addresses a traditionally challenging topic by equipping them with concrete tools, communication training, and clear treatment directives. From a societal perspective, primary care holds a unique position to identify hazardous and harmful alcohol use across different age groups, with potential public health and economic benefits through early identification and intervention. TRIAL REGISTRATION: Clinicaltrials.gov NCT05916027. Retrospectively registered 22 June 2023.


Subject(s)
Alcohol Deterrents , Alcoholism , Disulfiram , Naltrexone , Primary Health Care , Humans , Primary Health Care/organization & administration , Denmark , Naltrexone/therapeutic use , Naltrexone/analogs & derivatives , Alcoholism/diagnosis , Alcoholism/drug therapy , Alcoholism/therapy , Male , Female , Alcohol Deterrents/therapeutic use , Disulfiram/therapeutic use , Acamprosate/therapeutic use , Adult , Taurine/analogs & derivatives , Taurine/therapeutic use , Alanine Transaminase/blood , gamma-Glutamyltransferase/blood , Middle Aged , Mass Screening/methods , Randomized Controlled Trials as Topic
2.
Eur J Sport Sci ; 24(6): 824-833, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38874978

ABSTRACT

We investigated the associations of low handgrip strength (HGS, i.e., a marker of muscular fitness) with liver fat content (LFC) and serum liver enzymes in a population-based setting. We used data from 2700 participants (51.7% women), aged 21-90 years, from two independent cohorts of the population-based Study of Health in Pomerania (SHIP-START-2 and SHIP-TREND-0). Cross-sectional, multivariable adjusted regression models were performed to examine the associations of HGS with LFC, measured by magnetic resonance imaging and serum liver enzymes. We found significant inverse associations of HGS with both LFC and serum liver enzymes. Specifically, a 10-kg lower HGS was associated with a 0.59% (95% confidence interval [CI]: 0.24-0.94; p = 0.001) higher LFC, a 0.051 µkatal/L (95% CI: 0.005-0.097; p = 0.031) higher gamma-glutamyltransferase (GGT) concentration and a 0.010 µkatal/L (95% CI: 0.001-0.020; p = 0.023) higher aspartate aminotransferase (AST) concentration. The adjusted odds-ratio for prevalent hepatic steatosis (defined by a MRI-PDFF ≥5.1%) per 10-kg lower HGS was 1.21 (95% CI: 1.04-1.40; p = 0.014). When considering only obese individuals, those with low HGS had a 1.58% (95% CI: 0.18-2.98; p = 0.027) higher mean LFC and higher chance of prevalent hepatic steatosis (adjusted OR 1.74, 95% CI: 1.15-2.62; p = 0.009) compared to individuals with high HGS. We found similar associations in individuals with overweight, but not in those with normal weight. Lower HGS was strongly associated with both higher LFC and higher serum GGT and AST concentrations. Future studies might clarify whether these findings reflect adverse effects of a sedentary lifestyle or aging on the liver.


Subject(s)
Aspartate Aminotransferases , Hand Strength , Liver , gamma-Glutamyltransferase , Humans , Middle Aged , Female , Male , Adult , Aged , Cross-Sectional Studies , Aspartate Aminotransferases/blood , Liver/enzymology , Aged, 80 and over , gamma-Glutamyltransferase/blood , Young Adult , Germany/epidemiology , Magnetic Resonance Imaging , Sedentary Behavior , Fatty Liver/blood , Alanine Transaminase/blood
3.
Pediatr Surg Int ; 40(1): 146, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38822892

ABSTRACT

BACKGROUND: Biliary atresia (BA), a progressive condition affecting canalicular-bile duct function/anatomy, requires prompt surgical intervention for favorable outcomes. Therefore, we conducted a network meta-analysis of common diagnostic methods to assess their performance and provide evidence-based support for clinical decision-making. METHODS: We reviewed literature in PubMed, EMBASE, and Cochrane for BA diagnostics. The search included gamma-glutamyl transferase (GGT), direct/combined bilirubin, matrix metalloproteinase 7 (MMP-7), ultrasonic triangular cord sign (TCS), hepatic scintigraphy (HS), and percutaneous cholangiocholangiography/percutaneous transhepatic cholecysto-cholangiography (PCC/PTCC). QUADAS-2 assessed study quality. Heterogeneity and threshold effect were evaluated using I2 and Spearman's correlation. We combined effect estimates, constructed SROC models, and conducted a network meta-analysis based on the ANOVA model, along with meta-regression and subgroup analysis, to obtain precise diagnostic performance assessments for BA. RESULTS: A total of 40 studies were included in our analysis. GGT demonstrated high diagnostic accuracy for BA with a sensitivity of 81.5% (95% CI 0.792-0.836) and specificity of 72.1% (95% CI 0.693-0.748). Direct bilirubin/conjugated bilirubin showed a sensitivity of 87.6% (95% CI 0.833-0.911) but lower specificity of 59.4% (95% CI 0.549-0.638). MMP-7 exhibited a total sensitivity of 91.5% (95% CI 0.893-0.934) and a specificity of 84.3% (95% CI 0.820-0.863). TCS exhibited a sensitivity of 58.1% (95% CI 0.549-0.613) and high specificity of 92.9% (95% CI 0.911-0.944). HS had a high sensitivity of 98.4% (95% CI 0.968-0.994) and moderate specificity of 79.0% (95% CI 0.762-0.816). PCC/PTCC exhibited excellent diagnostic performance with a sensitivity of 100% (95% CI 0.900-1.000) and specificity of 87.0% (95% CI 0.767-0.939). Based on the ANOVA model, the network meta-analysis revealed that MMP-7 ranked second overall, with PCC/PTCC ranking first, both exhibiting superior diagnostic accuracy compared to other techniques. Our analysis showed no significant bias in most methodologies, but MMP-7 and hepatobiliary scintigraphy exhibited biases, with p values of 0.023 and 0.002, respectively. CONCLUSION: MMP-7 and ultrasound-guided PCC/PTCC show diagnostic potential in the early diagnosis of BA, but their clinical application is restricted due to practical limitations. Currently, the cutoff value of MMP-7 is unclear, and further evidence-based medical research is needed to firmly establish its diagnostic value. Until more evidence is available, MMP-7 is not suitable for widespread diagnostic use. Therefore, considering cost and operational simplicity, liver function tests combined with ultrasound remain the most clinically valuable non-invasive diagnostic methods for BA.


Subject(s)
Biliary Atresia , Biliary Atresia/diagnosis , Humans , Network Meta-Analysis , Early Diagnosis , gamma-Glutamyltransferase/blood , Sensitivity and Specificity
4.
Front Endocrinol (Lausanne) ; 15: 1393859, 2024.
Article in English | MEDLINE | ID: mdl-38854689

ABSTRACT

Background: Current guidelines for nonalcoholic fatty liver disease (NAFLD) recommend high volumes and/or intensities of physical activity (PA), the achievement of which generally requires participation in supervised exercise training programs that however are difficult to implement in routine clinical practice. Conversely, counselling interventions may be more suitable, but result in only modest increases in moderate-to-vigorous-intensity PA (MVPA). This study assessed whether a counseling intervention for increasing PA and decreasing sedentary time (SED-time) is effective in improving NAFLD markers in people with type 2 diabetes. Methods: Three-hundred physically inactive and sedentary patients were randomized 1:1 to receive one-month theoretical and practical counseling once-a-year (intervention group) or standard care (control group) for 3 years. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyltranspeptidase (γGT) levels were measured and fatty liver index (FLI), hepatic steatosis index (HSI), and visceral adiposity index (VAI) were calculated. Total PA volume, light-intensity PA (LPA), moderate-to-vigorous-intensity PA (MVPA), and SED-time were objectively measured by an accelerometer. Results: Throughout the 3-year period, NAFLD markers did not change in the control group, whereas ALT, γGT, FLI, and HSI decreased in the intervention group, with significant between-group differences, despite modest MVPA increases, which however were associated with larger decrements in SED-time and reciprocal increments in LPA. Mean changes in NAFLD markers varied according to quartiles of (and correlated with) changes in MVPA (all markers) and SED-time, LPA, and PA volume (ALT, γGT, and HSI). Mean changes in MVPA or PA volume were independent predictors of changes in NAFLD markers. When included in the models, change in cardiorespiratory fitness and lower body muscle strength were independently associated with some NAFLD markers. Conclusion: A behavior change involving all domains of PA lifestyle, even if insufficient to achieve the recommended MVPA target, may provide beneficial effects on NAFLD markers in people with type 2 diabetes.


Subject(s)
Alanine Transaminase , Aspartate Aminotransferases , Diabetes Mellitus, Type 2 , Exercise , Non-alcoholic Fatty Liver Disease , Sedentary Behavior , Humans , Diabetes Mellitus, Type 2/therapy , Male , Female , Middle Aged , Exercise/physiology , Non-alcoholic Fatty Liver Disease/therapy , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/metabolism , Liver/metabolism , Biomarkers , Aged , gamma-Glutamyltransferase/blood , gamma-Glutamyltransferase/metabolism
5.
BMC Cardiovasc Disord ; 24(1): 294, 2024 Jun 07.
Article in English | MEDLINE | ID: mdl-38849721

ABSTRACT

BACKGROUND: The incidence of hypertension (HTN) as a worldwide health problem is rising rapidly. Early identification and management of pre-HTN before HTN development can help reduce its related complications. We evaluated the relationship between liver enzymes levels and pre-HTN/HTN in the Azar cohort population. METHOD: This cross-sectional study was based on data from the large Azar cohort study and a total of 14,184 participants were included. Pre-HTN and HTN were defined based on the American Heart Association guideline. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) levels were measured by Pars Azmoon kits. The relationship between pre-HTN/HTN and liver enzyme levels was evaluated by logistic regression. RESULTS: Of 14,184 participants, 5.7% and 39.6% had pre-HTN and HTN, respectively. In the adjusted model, AST levels of 19-23 IU/l were associated with an elevated risk of pre-HTN (OR [95% CI]: 1.24 [1.04-1.48]). A dose-response increase was seen in pre-HTN in relation to ALT, with the highest OR in the third tertile (1.34 [1.09-1.63]). The odds of pre-HTN also increased with GGT in the third tertile (1.25[1.03-1.52]). In addition, the odds of HTN increased with increased levels of AST, ALT, ALP, and GGT, such that the highest ORs were recorded in the third tertile (OR 1.22 [1.09-1.37], 1.51 [1.35-1.70], 1.19 [1.07-1.34], and 1.68 [1.49-1.89], respectively). Among these enzymes, GGT had the highest OR regarding HTN. CONCLUSION: This study indicates that AST, ALT, ALP and GGT levels were associated with pre-HTN (except for ALP) and HTN, independent of known risk factors. Hence, it may be possible to use liver enzymes to predict the incidence of pre-HTN and HTN, empowering primary care providers to make the necessary interventions promptly.


Subject(s)
Alanine Transaminase , Alkaline Phosphatase , Aspartate Aminotransferases , Biomarkers , Blood Pressure , Hypertension , Liver , Prehypertension , gamma-Glutamyltransferase , Humans , Male , Hypertension/epidemiology , Hypertension/diagnosis , Hypertension/enzymology , Hypertension/blood , Female , Cross-Sectional Studies , Middle Aged , Alanine Transaminase/blood , gamma-Glutamyltransferase/blood , Biomarkers/blood , Alkaline Phosphatase/blood , Risk Factors , Adult , Aspartate Aminotransferases/blood , Liver/enzymology , Risk Assessment , Prehypertension/enzymology , Prehypertension/epidemiology , Prehypertension/diagnosis , Prehypertension/blood , Prehypertension/physiopathology , Clinical Enzyme Tests , Incidence , Predictive Value of Tests
6.
Front Endocrinol (Lausanne) ; 15: 1325230, 2024.
Article in English | MEDLINE | ID: mdl-38818508

ABSTRACT

Introduction: Polycystic ovary syndrome (PCOS) is often associated with metabolic-associated fatty liver disease (MAFLD). MAFLD has been associated with altered hepatic function, systemic dysmetabolism, and abnormal circulating levels of signaling molecules called organokines. Here, we assessed the effects of two randomized treatments on a set of organokines in adolescent girls with PCOS and without obesity, and report the associations with circulating biomarkers of liver damage, which were assessed longitudinally in the aforementioned studies as safety markers. Materials and methods: Liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT)] were assessed as safety markers in previous randomized pilot studies comparing the effects of an oral contraceptive (OC) with those of a low-dose combination of spironolactone-pioglitazone-metformin (spiomet) for 1 year. As a post hoc endpoint, the organokines fibroblast growth factor-21 (FGF21), diazepam-binding protein-1 (DBI), and meteorin-like protein (METRNL) were assessed by ELISA after 6 months of OC (N = 26) or spiomet (N = 28). Auxological, endocrine-metabolic, body composition (using DXA), and abdominal fat partitioning (using MRI) were also evaluated. Healthy, age-matched adolescent girls (N = 17) served as controls. Results: Circulating ALT and GGT levels increased during OC treatment and returned to baseline concentrations in the post-treatment phase; in contrast, spiomet treatment elicited no detectable changes in ALT and GGT concentrations. In relation to organokines after 6 months of treatment, (1) FGF21 levels were significantly higher in PCOS adolescents than in control girls; (2) DBI levels were lower in OC-treated girls than in controls and spiomet-treated girls; and (3) no differences were observed in METRNL concentrations between PCOS girls and controls. Serum ALT and GGT levels were directly correlated with circulating METRNL levels only in OC-treated girls (R = 0.449, P = 0.036 and R = 0.552, P = 0.004, respectively). Conclusion: The on-treatment increase in ALT and GGT levels occurring only in OC-treated girls is associated with circulating METRNL levels, suggesting enhanced METRNL synthesis as a reaction to the hepatic changes elicited by OC treatment. Clinical Trial Registration: https://doi.org, identifiers 10.1186/ISRCTN29234515, 10.1186/ISRCTN11062950.


Subject(s)
Alanine Transaminase , Fibroblast Growth Factors , Liver , Metformin , Polycystic Ovary Syndrome , Humans , Female , Polycystic Ovary Syndrome/drug therapy , Polycystic Ovary Syndrome/metabolism , Polycystic Ovary Syndrome/blood , Adolescent , Metformin/therapeutic use , Fibroblast Growth Factors/blood , Fibroblast Growth Factors/metabolism , Liver/drug effects , Liver/metabolism , Alanine Transaminase/blood , Alanine Transaminase/metabolism , Pioglitazone/therapeutic use , Biomarkers/blood , Spironolactone/therapeutic use , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/metabolism , gamma-Glutamyltransferase/blood , gamma-Glutamyltransferase/metabolism , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/metabolism , Contraceptives, Oral/adverse effects , Contraceptives, Oral/therapeutic use , Contraceptives, Oral/administration & dosage , Hypoglycemic Agents/therapeutic use
7.
Ren Fail ; 46(1): 2353339, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38770975

ABSTRACT

OBJECTIVES: Peritoneal dialysis (PD) serves as a vital renal replacement therapy for patients with end-stage kidney disease (ESKD). γ-Gamma-glutamyl transferase (γ-GGT) is a recognized predictor of oxidative stress and mortality. This study aimed to assess the prognostic significance of γ-GGT in predicting all-cause and cardiovascular mortality among PD patients. METHODS: A retrospective study was conducted, enrolling 640 PD patients from a single center. The one-year, three-year, and five-year mortality rates for all causes and cardiovascular causes were evaluated. Kaplan-Meier survival analysis and multivariate Cox regression analysis were performed. RESULTS: Within five years of initiating PD, the observed all-cause mortality rates at one, three, and five years were 11.72%, 16.09%, and 23.44%, while cardiovascular mortality rates were 2.97%, 7.34%, and 11.09%, respectively. Lower γ-GGT levels were associated with decreased all-cause mortality during one-, three-, and five-year follow-ups, along with reduced cardiovascular mortality in the first and third years, as indicated by Kaplan-Meier analysis on median γ-GGT groupings. Multivariate Cox regression analysis showed significantly decreased hazard ratios (HRs) for one- to five-year all-cause mortality and cardiovascular mortality in the lower γ-GGT group compared to higher groups. However, when sex differences were eliminated using separate tertile groupings for males and females, only the one- and three-year all-cause mortality rates demonstrated significantly reduced hazard ratios (HRs) in the lower γ-GGT groups. CONCLUSION: This retrospective study suggests that γ-GGT levels have prognostic significance in predicting one- and three-year all-cause mortality among PD patients when accounting for sex differences.


Subject(s)
Cardiovascular Diseases , Kaplan-Meier Estimate , Kidney Failure, Chronic , Peritoneal Dialysis , gamma-Glutamyltransferase , Humans , Male , Female , Retrospective Studies , Middle Aged , Peritoneal Dialysis/mortality , Kidney Failure, Chronic/therapy , Kidney Failure, Chronic/mortality , Cardiovascular Diseases/mortality , gamma-Glutamyltransferase/blood , Adult , Prognosis , Aged , Cause of Death , Proportional Hazards Models
8.
BMC Cancer ; 24(1): 617, 2024 May 21.
Article in English | MEDLINE | ID: mdl-38773511

ABSTRACT

BACKGROUND: Hepatocellular carcinoma (HCC) presents a significant threat to individuals and healthcare systems due to its high recurrence rate. Accurate prognostic models are essential for improving patient outcomes. Gamma-glutamyl transpeptidase (GGT) and prealbumin (PA) are biomarkers closely related to HCC. This study aimed to investigate the predictive value of the GGT to PA ratio (GPR) and to construct prognostic nomograms for HCC patients without microvascular invasion. METHODS: We retrospectively analyzed data from 355 HCC patients who underwent radical hepatectomy at Shengjing Hospital of China Medical University between December 2012 and January 2021. Patients were randomly assigned to a training cohort (n = 267) and a validation cohort (n = 88). The linearity of GPR was assessed using restricted cubic spline (RCS) analysis, and the optimal cut-off value was determined by X-tile. Kaplan-Meier survival curves and log-rank tests were used to investigate the associations between GPR and both progression-free survival (PFS) and overall survival (OS). Cox multivariate regression analysis identified independent risk factors, enabling the construction of nomograms. Time-dependent receiver operating characteristic (ROC) and calibration curves were used to evaluate the accuracy of the nomograms. Decision curve analysis (DCA) assessed the predictive value of the models. RESULTS: Patients were categorized into GPR-low and GPR-high groups based on a GPR value of 333.33. Significant differences in PFS and OS were observed between the two groups (both P < 0.001). Cox multivariate analysis identified GPR as an independent risk factor for both PFS (OR = 1.80, 95% CI: 1.24-2.60, P = 0.002) and OS (OR = 1.87, 95% CI: 1.07-3.26, P = 0.029). The nomograms demonstrated good predictive performance, with C-index values of 0.69 for PFS and 0.76 for OS. Time-dependent ROC curves and calibration curves revealed the accuracy of the models in both the training and validation cohorts, with DCA results indicating notable clinical value. CONCLUSIONS: GPR emerged as an independent risk factor for both OS and PFS in HCC patients without microvascular invasion. The nomograms based on GPR demonstrated relatively robust predictive efficiency for prognosis.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Nomograms , Prealbumin , gamma-Glutamyltransferase , Humans , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/mortality , Carcinoma, Hepatocellular/blood , Carcinoma, Hepatocellular/surgery , Liver Neoplasms/pathology , Liver Neoplasms/mortality , Liver Neoplasms/blood , Liver Neoplasms/surgery , Female , Male , Middle Aged , gamma-Glutamyltransferase/blood , gamma-Glutamyltransferase/metabolism , Retrospective Studies , Prognosis , Prealbumin/analysis , Prealbumin/metabolism , Biomarkers, Tumor/blood , Biomarkers, Tumor/metabolism , Hepatectomy , Adult , Aged , ROC Curve , Neoplasm Invasiveness , Kaplan-Meier Estimate , Microvessels/pathology , Predictive Value of Tests
9.
Diab Vasc Dis Res ; 21(3): 14791641241252553, 2024.
Article in English | MEDLINE | ID: mdl-38702054

ABSTRACT

OBJECTIVE: To evaluate the association between GGT/HDL-C ratio and resolution of MetS in adults after sleeve gastrectomy (SG). METHODS: We conducted a retrospective cohort study using secondary data from a Peruvian bariatric center. The study population consisted of adults aged 18 and above who underwent laparoscopic SG and were diagnosed with MetS prior to the surgery. The main outcome measured was MetS resolution 6 months post-surgery and the exposure variable was the GGT/HDL-C ratio. RESULTS: We analyzed 137 patients with a mean age of 38.9 ± 10.9 years; 64.2% were females. The median GGT/HDL-C ratio was 1.1 [0.7 - 1.5], and 83.9% of patients experienced resolution of MetS. Furthermore, both the middle tertile of GGT/HDL-C (aRR: 1.28; 95% CI: 1.04 - 1.58; p = .019) and the lowest tertile (aRR: 1.27; 95% CI: 1.01 - 1.60; p = .038) showed a significant association with the resolution of MetS. CONCLUSION: Eight out of 10 patients undergoing SG experience resolution of MetS within 6 months after surgery. Patients in the middle and lower tertiles of the GGT/HDL-C were more likely to achieve this outcome. Therefore, the GGT/HDL-C ratio should be considered a valuable and efficient biomarker for preoperative assessment of bariatric surgery candidates.


Subject(s)
Biomarkers , Cholesterol, HDL , Gastrectomy , Metabolic Syndrome , gamma-Glutamyltransferase , Humans , Female , Adult , Male , Retrospective Studies , Metabolic Syndrome/blood , Metabolic Syndrome/diagnosis , Middle Aged , Biomarkers/blood , Cholesterol, HDL/blood , Treatment Outcome , gamma-Glutamyltransferase/blood , Time Factors , Gastrectomy/adverse effects , Peru , Predictive Value of Tests , Obesity, Morbid/surgery , Obesity, Morbid/blood , Obesity, Morbid/complications , Remission Induction , Weight Loss , Laparoscopy/adverse effects , Risk Factors , Bariatric Surgery/adverse effects
10.
Environ Toxicol Pharmacol ; 108: 104463, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38734395

ABSTRACT

Phthalates can induce hepatotoxicity in animal studies. We aimed to assess the associations of individual and mixture of urinary phthalate metabolites with serum liver function indicators among 764 women undergoing assisted reproductive technology (ART). In linear models, we observed inverse correlations between urinary mono-benzyl phthalate and serum total protein (TP) as well as globulin (ß=-0.27 and -0.23, respectively, P<0.05). Additionally, negative associations were identified between mono-isobutyl phthalate and mono-butyl phthalate (MBP) and aspartate aminotransferase-to-alanine transaminase ratio (AST/ALT) (P<0.05). MBP and the sum of all phthalate metabolites (∑all.phth.m) were positively associated with bilirubin, with ß ranging from 0.14 to 0.47. Most phthalate metabolites were also positively related to gamma-glutamyl transferase (GGT) (all P<0.05). In Bayesian kernel machine regression models, phthalate mixture was positively associated with bilirubin and GGT, whereas inversely associated with AST/ALT and TP. Our results suggest that phthalate exposure may impair liver function among women undergoing ART.


Subject(s)
Liver , Phthalic Acids , Reproductive Techniques, Assisted , Humans , Female , Phthalic Acids/urine , Phthalic Acids/toxicity , Adult , Liver/drug effects , Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Bilirubin/blood , Bilirubin/urine , Liver Function Tests , gamma-Glutamyltransferase/blood , gamma-Glutamyltransferase/urine , Environmental Pollutants/urine , Environmental Pollutants/toxicity , Environmental Pollutants/blood , Environmental Exposure/adverse effects
11.
Expert Opin Pharmacother ; 25(7): 925-935, 2024 May.
Article in English | MEDLINE | ID: mdl-38804904

ABSTRACT

INTRODUCTION: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is estimated to affect upto 70-80% of people with type 2 diabetes mellitus (T2DM). Although several anti-hyperglycemic drugs have been shown to be effective in such patients, there remains an unmet need for newer drugs. The objective of this meta-analysis was to analyze the effect of ipragliflozin on aspartate aminotransferase (AST), alanine transaminase (ALT), and gamma-glutamyl transpeptidase (GGT) levels in patients with T2DM. METHODS: A literature search on electronic databases was conducted to identify potential randomized clinical trials (RCT) as per predetermined study selection criteria. Mean difference (MD) was calculated using Cochrane review manager. RESULTS: Twelve studies were included in the meta-analysis, including 1349 subjects. Compared to the control group, ipragliflozin as a monotherapy showed a significant reduction in levels of ALT at week 12 (p = 0.02) and at week 24 (p = 0.007), GGT at week 12 (p < 0.00001). Ipragliflozin as an add-on therapy showed significant reduction in levels of AST at week 24 (p < 0.00001), ALT at week 12 (p = 0.002), ALT at week 24 (p < 0.00001), and GGT at week 24 (p < 0.00001). CONCLUSION: Findings suggest the beneficial effects of ipragliflozin on liver enzymes. Further large-scale RCTs are required to confirm ipragliflozin's role for liver-related conditions in T2DM.


Subject(s)
Alanine Transaminase , Aspartate Aminotransferases , Diabetes Mellitus, Type 2 , Glucosides , Hypoglycemic Agents , Randomized Controlled Trials as Topic , Thiophenes , gamma-Glutamyltransferase , Humans , Diabetes Mellitus, Type 2/drug therapy , Thiophenes/therapeutic use , gamma-Glutamyltransferase/blood , Hypoglycemic Agents/therapeutic use , Glucosides/therapeutic use , Glucosides/administration & dosage , Aspartate Aminotransferases/blood , Aspartate Aminotransferases/metabolism , Alanine Transaminase/blood , Liver/enzymology , Liver/drug effects , Fatty Liver/drug therapy , Drug Therapy, Combination , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Sodium-Glucose Transporter 2 Inhibitors/pharmacology
12.
Cell Mol Biol (Noisy-le-grand) ; 70(5): 139-144, 2024 May 27.
Article in English | MEDLINE | ID: mdl-38814225

ABSTRACT

The purpose of this study was to explore the association between miR-210 and serum GGT, ALP and AST levels in patients with choledocholithiasis. The clinical data of 82 patients with biliary stones admitted to the hospital from May 2020 to May 2022 were collected and divided into observation group (n=40) and control group (n=42) according to whether asymptomatic combined. The relative expression level of miR-210 was measured by RT-PCR, serum GGT, ALP, and AST by rate method, and the correlation of miR-210 expression level with serum GGT, ALP, AST and the diagnostic value for choledochal stones was analyzed. The relative expression of serum GGT, ALP, AST and miR-210 were all higher than the control group (P <0.05); the relative expression level of miR-210 and serum GGT, ALP and AST, 0.756, 0.832, 0.326, r = P <0.05), 0.782, 0.776, 0.681, 0.568, respectively. Serum miR-210 level was upregulated in patients with choledocholithiasis, and its expression was positively correlated with serum GGT, ALP, and AST, which can be used for early auxiliary diagnosis of choledocholithiasis.


Subject(s)
Alkaline Phosphatase , Aspartate Aminotransferases , Choledocholithiasis , MicroRNAs , gamma-Glutamyltransferase , Humans , Choledocholithiasis/blood , Choledocholithiasis/genetics , Choledocholithiasis/diagnosis , MicroRNAs/blood , MicroRNAs/genetics , Alkaline Phosphatase/blood , Male , Female , Middle Aged , gamma-Glutamyltransferase/blood , Aspartate Aminotransferases/blood , Adult , Case-Control Studies , Aged , ROC Curve
13.
BMC Gastroenterol ; 24(1): 183, 2024 May 24.
Article in English | MEDLINE | ID: mdl-38783185

ABSTRACT

OBJECTIVE: To evaluate the diagnostic accuracy of aspartate aminotransferase(AST)/ alanine transaminase (ALT), AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4) and gamma-glutamyl transpeptidase to platelet count ratio (GPR) for hepatic fibrosis in patients with chronic hepatitis B (CHB). METHODS: A total of 1210 CHB patients who underwent liver biopsy were divided into two groups: patients with no significant fibrosis (control group) and patients with significant fibrosis, and routine laboratory tests were retrospectively included. Logistic regression models were used for the prediction, and the area under the receiver operating characteristic (AUROC) was used to assess the diagnostic accuracy. RESULTS: A total of 631 (52.1%) and 275 (22.7%) patients had significant fibrosis (≥ S2) and advanced fibrosis (≥ S3), respectively. The GPR showed significantly higher diagnostic accuracy than that of APRI, FiB-4, and AST/ALT to predict ≥ S2(significant fibrosis) and ≥ S3 fibrosis(advanced fibrosis), with an AUROC was 0.69 (95%CI: 0.66-0.71) and 0.72 (0.69-0.75), respectively. After stratified by the status of HBeAg ( positive or negative), GPR, APRI, and FiB-4 showed improved predicting performance for significant fibrosis and advanced fibrosis in HBeAg positive patients, with the most significant improvement was shown for GPR in predicting significant fibrosis (AUROC = 0.74, 95%CI: 0.70-0.78). CONCLUSIONS: Among the four noninvasive models, GPR has the best performance in the diagnosis of hepatic fibrosis in CHB patients and is more valuable in HBeAg-positive patients.


Subject(s)
Alanine Transaminase , Aspartate Aminotransferases , Hepatitis B, Chronic , Liver Cirrhosis , gamma-Glutamyltransferase , Humans , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/pathology , Hepatitis B, Chronic/blood , Liver Cirrhosis/blood , Liver Cirrhosis/pathology , Liver Cirrhosis/diagnosis , Male , Female , Platelet Count , Aspartate Aminotransferases/blood , Adult , Alanine Transaminase/blood , Retrospective Studies , gamma-Glutamyltransferase/blood , Middle Aged , ROC Curve , Biopsy , Liver/pathology , Hepatitis B e Antigens/blood , Biomarkers/blood , Logistic Models , Predictive Value of Tests , Severity of Illness Index
14.
Sci Rep ; 14(1): 10726, 2024 05 10.
Article in English | MEDLINE | ID: mdl-38730095

ABSTRACT

Although patients with alpha-fetoprotein-negative hepatocellular carcinoma (AFPNHCC) have a favorable prognosis, a high risk of postoperative recurrence remains. We developed and validated a novel liver fibrosis assessment index, the direct bilirubin-gamma-glutamyl transpeptidase-to-platelet ratio (DGPRI). DGPRI was calculated for each of the 378 patients with AFPNHCC who underwent hepatic resection. The patients were divided into high- and low-score groups using the optimal cutoff value. The Lasso-Cox method was used to identify the characteristics of postoperative recurrence, followed by multivariate Cox regression analysis to determine the independent risk factors associated with recurrence. A nomogram model incorporating the DGPRI was developed and validated. High DGPRI was identified as an independent risk factor (hazard ratio = 2.086) for postoperative recurrence in patients with AFPNHCC. DGPRI exhibited better predictive ability for recurrence 1-5 years after surgery than direct bilirubin and the gamma-glutamyl transpeptidase-to-platelet ratio. The DGPRI-nomogram model demonstrated good predictive ability, with a C-index of 0.674 (95% CI 0.621-0.727). The calibration curves and clinical decision analysis demonstrated its clinical utility. The DGPRI nomogram model performed better than the TNM and BCLC staging systems for predicting recurrence-free survival. DGPRI is a novel and effective predictor of postoperative recurrence in patients with AFPNHCC and provides a superior assessment of preoperative liver fibrosis.


Subject(s)
Carcinoma, Hepatocellular , Hepatectomy , Liver Cirrhosis , Liver Neoplasms , Neoplasm Recurrence, Local , Nomograms , alpha-Fetoproteins , gamma-Glutamyltransferase , Humans , Carcinoma, Hepatocellular/surgery , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/blood , Liver Neoplasms/surgery , Liver Neoplasms/pathology , Liver Neoplasms/blood , Male , Female , Liver Cirrhosis/pathology , Liver Cirrhosis/surgery , Liver Cirrhosis/blood , Middle Aged , Retrospective Studies , Neoplasm Recurrence, Local/pathology , gamma-Glutamyltransferase/blood , Hepatectomy/adverse effects , alpha-Fetoproteins/metabolism , alpha-Fetoproteins/analysis , Aged , Prognosis , Bilirubin/blood , Risk Factors , Platelet Count , Adult
15.
Zhonghua Gan Zang Bing Za Zhi ; 32(4): 325-331, 2024 Apr 20.
Article in Chinese | MEDLINE | ID: mdl-38733187

ABSTRACT

Objective: To analyze the hepatic tissue inflammatory activity and influencing factors in HBeAg-positive patients during normal alanine aminotransferase (ALT) and indeterminate phases so as to provide a basis for evaluating the disease condition. Methods: Patients with HBeAg-positive with normal ALT and HBV DNA levels below 2 × 10(7) IU/ml from January 2017 to December 2021 were selected as the study subjects. A histopathologic liver test was performed on these patients. Age, gender, time of HBV infection, liver function, HBsAg level, HBV DNA load, genotype, portal vein inner diameter, splenic vein inner diameter, splenic thickness, and others of the patients were collected. Significant influencing factors of inflammation were analyzed in patients using logistic regression analysis, and its effectiveness was evaluated using receiver operating characteristic (ROC) curves. Results: Of the 178 cases, there were 0 cases of inflammation in G0, 52 cases in G1, 101 cases in G2, 24 cases in G3, and one case in G4. 126 cases (70.8%) had inflammatory activity ≥ G2. Infection time (Z=-7.138, P<0.001), γ-glutamyltransferase (t =-2.940, P=0.004), aspartate aminotransferase (t =-2.749, P=0.007), ALT (t =-2.153, P=0.033), HBV DNA level (t =-4.771, P=0.010) and portal vein inner diameter (t =-4.771, P<0.001) between the ≥G2 group and < G2 group were statistically significantly different. A logistic regression analysis showed that significant inflammation in liver tissue was independently correlated with infection time [odds ratio (OR)=1.437, 95% confidence interval (CI): 1.267-1.630; P<0.001)] and portal vein inner diameter (OR=2.738, 95% CI: 1.641, 4.570; P<0.001). The area under the curve (AUROC), specificity, and sensitivity for infection time and portal vein inner diameter were 0.84, 0.71, 0.87, 0.72, 0.40, and 0.95, respectively. Conclusion: A considerable proportion of HBeAg-positive patients have inflammation grade ≥G2 during normal ALT and indeterminate phases, pointing to the need for antiviral therapy. Additionally, inflammatory activity has a close association with the time of infection and portal vein inner diameter.


Subject(s)
Alanine Transaminase , Hepatitis B e Antigens , Hepatitis B virus , Liver , Humans , Liver/pathology , Alanine Transaminase/blood , Hepatitis B e Antigens/blood , Inflammation , DNA, Viral , Male , Hepatitis B, Chronic/pathology , Female , Logistic Models , ROC Curve , Portal Vein , Hepatitis B , gamma-Glutamyltransferase/blood , Adult
16.
J Diabetes ; 16(5): e13551, 2024 May.
Article in English | MEDLINE | ID: mdl-38664890

ABSTRACT

BACKGROUND: There exists a paucity of data regarding whether gamma-glutamyl transferase is associated with disease-specific mortality in patients with type 2 diabetes mellitus. This study aimed to investigate the association of serum gamma-glutamyl transferase levels with all-cause and disease-specific mortality in patients with diabetes mellitus using a Korean nationwide health-screening database. METHODS: A total of 9 687 066 patients without viral hepatitis or liver cirrhosis who underwent health examination in 2009 were included. These patients were divided into four groups according to sex-specific quartiles of serum gamma-glutamyl transferase levels. RESULTS: During a median follow-up period of 8.1 years, 222 242 deaths were identified. The all-cause mortality rate increased as the serum gamma-glutamyl transferase levels became higher (highest quartile vs lowest quartile: hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.55-1.59; p for trend <.001). Similar trends were observed for cardiovascular disease (HR, 1.57; 95% CI, 1.53-1.62), ischemic heart disease (HR, 1.40; 95% CI, 1.33-1.48), and stroke (HR, 1.72; 95% CI, 1.60-1.85) in the highest quartile, as compared with the lowest quartile (p for trend <.001). As the gamma-glutamyl transferase quartiles became higher, mortality rates related to cancer (HR, 1.56; 95% CI, 1.52-1.60), liver disease (HR, 9.42; 95% CI, 8.81-10.07), respiratory disease (HR, 1.55; 95% CI, 1.49-1.62), and infectious disease (HR, 1.73; 95% CI, 1.59-1.87) also increased in the highest quartile, compared with the lowest quartile (p for trend <.001). CONCLUSIONS: Serum gamma-glutamyl transferase levels may be useful for the risk assessment of all-cause and disease-specific mortality among patients with type 2 diabetes mellitus.


Subject(s)
Diabetes Mellitus, Type 2 , gamma-Glutamyltransferase , Humans , gamma-Glutamyltransferase/blood , Male , Female , Middle Aged , Diabetes Mellitus, Type 2/mortality , Diabetes Mellitus, Type 2/blood , Republic of Korea/epidemiology , Risk Factors , Aged , Cause of Death , Adult , Cohort Studies , Cardiovascular Diseases/mortality , Cardiovascular Diseases/blood , Biomarkers/blood , Neoplasms/mortality , Neoplasms/blood , Follow-Up Studies
17.
Diabetes Res Clin Pract ; 211: 111649, 2024 May.
Article in English | MEDLINE | ID: mdl-38574896

ABSTRACT

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has become the most frequent liver disease, closely related with metabolic risk factors such as obesity, insulin resistance, dyslipidemia, diabetes mellitus, and metabolic syndrome. In this context, γ-Glutamyl transpeptidase (GGT) and high-density lipoprotein cholesterol (HDL-C) have shown correlations with steatosis severity and metabolic syndrome, respectively. This positions the GGT/HDL-C ratio as a potential diagnostic indicator for NAFLD. OBJECTIVE: To assess the diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery. METHODS: We conducted an analytical cross-sectional study, designed as a diagnostic test evaluation. A secondary database of 249 adults with obesity was analyzed. The optimal cut-off point was ascertained using three methodologies, and five adjustment models were constructed for the total population, further stratified by sex. RESULTS: The optimal cut-off point was 20.5 U/mmol and the AUC of the ratio was 0.81 (95% CI: 0.64-0.98), with sensitivity and specificity being 82.5% and 77.8%, respectively. In the overall group with an elevated GGT/HDL-C ratio, the prevalence of NAFLD increased by 14% (PR: 1.14; 95% CI: 1.04-1.33). Specifically, women displaying this altered ratio showed a 19% increased prevalence (PR: 1.19; 95% CI: 1.07-1.42) compared to those with normal values. CONCLUSIONS: The GGT/HDL-C ratio is a promising biomarker for the diagnosis of NAFLD in an adult population living with obesity.


Subject(s)
Bariatric Surgery , Cholesterol, HDL , Non-alcoholic Fatty Liver Disease , Obesity , gamma-Glutamyltransferase , Humans , Non-alcoholic Fatty Liver Disease/diagnosis , Non-alcoholic Fatty Liver Disease/blood , Non-alcoholic Fatty Liver Disease/complications , Female , Male , gamma-Glutamyltransferase/blood , Cross-Sectional Studies , Adult , Middle Aged , Cholesterol, HDL/blood , Obesity/complications , Obesity/blood , Obesity/surgery , Biomarkers/blood
18.
Biochem Med (Zagreb) ; 34(2): 020705, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38665867

ABSTRACT

Introduction: This study aimed to examine whether the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) reference intervals for 19 commonly used biochemical assays (potassium, sodium, chloride, calcium, magnesium, inorganic phosphorous, glucose, urea, creatinine, direct and total bilirubin, C-reactive protein (CRP), total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP) and lactate dehydrogenase (LD)) could be applied to the newborn population of one Croatian clinical hospital. Materials and methods: Reference interval verification was performed according to the CLSI EP28-A3c guidelines. Samples of healthy newborns were selected using the direct a posteriori sampling method and analyzed on the Beckman Coulter AU680 biochemical analyzer. If verification wasn't satisfactory, further procedure included de novo determination of own reference intervals by analyzing 120 samples of healthy newborns. Results: After the first set of measurements, 14/19 tested reference intervals were adopted for use: calcium, inorganic phosphorous, glucose, urea, creatinine, total bilirubin, CRP, total protein, albumin, AST, ALT, GGT, ALP and LD. A second set of samples was tested for 5 analytes: potassium, sodium, chloride, magnesium and direct bilirubin. The verification results of the additional samples for sodium and chloride were satisfactory, while the results for potassium, magnesium and direct bilirubin remained unsatisfactory and new reference intervals were determined. Conclusions: The CALIPER reference intervals can be implemented into routine laboratory and clinical practice for the tested newborn population for most of the analyzed assays, while own reference intervals for potassium, magnesium and direct bilirubin have been determined.


Subject(s)
Bilirubin , Humans , Infant, Newborn , Reference Values , Croatia , Bilirubin/blood , Male , Female , C-Reactive Protein/analysis , Creatinine/blood , Aspartate Aminotransferases/blood , Alanine Transaminase/blood , Blood Chemical Analysis/standards , gamma-Glutamyltransferase/blood , Alkaline Phosphatase/blood , Potassium/blood , Magnesium/blood , L-Lactate Dehydrogenase/blood , Chlorides/blood , Calcium/blood , Blood Glucose/analysis , Sodium/blood
19.
Zhonghua Er Ke Za Zhi ; 62(5): 462-466, 2024 May 02.
Article in Chinese | MEDLINE | ID: mdl-38623015

ABSTRACT

Objective: To analyze the clinical manifestations, pathology, and gene variant characteristics in children with progressive familial intrahepatic cholestasis type 3 (PFIC3). Methods: This retrospective study assessed the clinical manifestations, pathological features, gene variants, and prognosis data of 11 children with PFIC3 hospitalized in the Department of Hepatology, Fifth Medical Center, PLA General Hospital, from January 2015 to December 2022. Panel or whole exome sequencing was performed on the probands, followed by Sanger sequencing for verification within the family. Detected pathogenic variants were compared with known disease databases. Additionally, the new variants were predicted the deleteriousness and protein structure using relevant software to evaluate their pathogenicity. Results: Among the 11 PFIC3 children, 8 were boys and 3 were girls. The age of onset was 3.1 (0.2, 15.6) years. The main complaint of onset was different in the 11 patients;5 of them were abnormal liver function, 3 of them were liver and spleen enlargement, 2 of them were abdominal distension, and 1 of them was jaundice. Alanine aminotransferase, asparate aminotransferase and γ-glutamyltransferase increased in all the patients, which were(113±40), (150±44) and (270±156) U/L respectively. Moreover, direct bilirubin increased in 9 patients, and cholestasis was showed in 8 patients. All patients showed liver fibrosis on imaging, and 8 patients had cirrhosis. The pathological features of 8 cases by liver biopsy were as follows: 8 cases of fibrosis in the portal area, 7 cases of small bile duct hyperplasia, 4 cases of positive copper staining, and 5 cases of cirrhosis. A total of 17 ABCB4 gene variants were detected, including 9 new variants: c.589C>T(p.Q197X), c.1230+1G>A(Splicing), c.2914G>A(P.D972N), c.1058G>A(p.C353Y), c.956G>T(p.G319V), c.473T>A(p.L158Q), c.164T>C(p.L55S), c.2493G>C(p.R831S), and c.1150G>C(p.G384R). All 11 patients were treated with ursodeoxycholic acid and followed up for 5.1(0.6, 7.4) years. Among them, 4 cases of cirrhosis progressed continuously, 3 cases had liver transplantations, and the remaining 4 cases were stable after medical treatment. Conclusions: Children with PFIC3 have early onset, diverse clinical manifestations, rapid progression of fibrotic and cholestasis, as well as poor prognosis. Genetic testing helps to confirm the diagnosis.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B/deficiency , Cholestasis, Intrahepatic , Exome Sequencing , Humans , Male , Female , Cholestasis, Intrahepatic/genetics , Cholestasis, Intrahepatic/diagnosis , Retrospective Studies , Child , Child, Preschool , Infant , Adolescent , Mutation , Liver/pathology , gamma-Glutamyltransferase/blood , Alanine Transaminase/blood , ATP Binding Cassette Transporter, Subfamily B/genetics , Prognosis , Aspartate Aminotransferases/blood
20.
Korean J Gastroenterol ; 83(4): 163-166, 2024 Apr 25.
Article in English | MEDLINE | ID: mdl-38659253

ABSTRACT

Malignant melanoma (MM) is an aggressive tumor that can metastasize to any organ, but biliary tract metastasis is scarce. We describe a very rare case of MM metastasis to the common bile duct (CBD), presented with only dyspeptic symptoms. The patient had mildly elevated alkaline phosphatase and gamma-glutamyl transferase levels. Magnetic resonance cholangiopancreatography demonstrated a dilated common bile duct with a distal stricture. The MM diagnosis was established with the ampulla of Vater biopsy specimens obtained by endoscopic retrograde cholangiopancreatography (ERCP), and the patient's symptoms were resolved after biliary stenting. Both primary CBD cancer and other cancer types like MM that metastasize to CBD can cause obstruction and can be manifested only by dyspeptic symptoms. MM metastasis to CBD can cause obstruction manifested only by dyspeptic symptoms without obstructive jaundice. ERCP can be employed as a promising option for treatment and diagnosis. New-onset dyspeptic symptoms in patients with a history of MM should be investigated thoroughly, especially in the context of biliary metastasis.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde , Cholangiopancreatography, Magnetic Resonance , Dyspepsia , Melanoma , Tomography, X-Ray Computed , Humans , Melanoma/diagnosis , Melanoma/secondary , Melanoma/pathology , Melanoma/complications , Dyspepsia/diagnosis , Dyspepsia/etiology , Male , Middle Aged , Common Bile Duct/pathology , gamma-Glutamyltransferase/blood , Common Bile Duct Neoplasms/diagnosis , Common Bile Duct Neoplasms/pathology , Common Bile Duct Neoplasms/complications , Common Bile Duct Neoplasms/secondary , Alkaline Phosphatase/blood , Alkaline Phosphatase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...